Cite
HARVARD Citation
Nysom, K. et al. (n.d.). HGG-18. Long-term efficacy and safety of larotrectinib in paediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumours. Neuro-oncology. p. i64. [Online].